Business context and reporting period
UnitedHealth Group’s Form 10-K covers the fiscal year ended December 31, 2023; it reports full-year results, not standalone fourth-quarter results. The company operates UnitedHealthcare, a health benefits business, and Optum, which includes care delivery, health technology and analytics, and pharmacy services.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $371.6 billion | $324.2 billion | +15% |
| Earnings from operations | $32.4 billion | $28.4 billion | +14% |
| Net earnings attributable to common shareholders | $22.4 billion | $20.1 billion | +11% |
| Diluted earnings per share | $23.86 | $21.18 | +13% |
| Cash flows from operations | $29.1 billion | $26.2 billion | +$2.9 billion |
| Medical care ratio (MCR) | 83.2% | 82.0% | +1.2 percentage points |
| Operating margin | 8.7% | 8.8% | -0.1 percentage points |
| Net earnings margin | 6.0% | 6.2% | -0.2 percentage points |
Revenue growth reflected more people served, pricing, growth across Optum and higher investment income. Medical costs rose 15%, faster than premiums, with management citing increased care activity—particularly outpatient care for seniors—and business mix. Investment and other income more than doubled to $4.1 billion, partly reflecting higher interest rates. Interest expense increased 55% to $3.2 billion.
By segment, UnitedHealthcare revenue grew 13% to $281.4 billion and operating earnings rose 14% to $16.4 billion; its operating margin was 5.8%, unchanged. Optum revenue grew 24% to $226.6 billion and operating earnings rose 13% to $15.9 billion; Optum’s operating margin declined to 7.0% from 7.7%. Optum Health revenue increased 34%, but its margin fell to 6.9% from 8.5%; Optum Insight revenue increased 30% and margin fell to 22.5% from 24.6%; Optum Rx revenue increased 16% and margin was 4.4%, unchanged.
At year-end, cash and cash equivalents were $25.4 billion, of which $1.3 billion was available for general corporate use. Cash, cash equivalents and investments totaled $75.2 billion. Total short- and long-term debt was approximately $61.5 billion; the company reported a 38% debt-to-debt-plus-equity ratio under its credit agreements and compliance with debt covenants. Operating cash flow funded, among other uses, $10.1 billion of acquisitions, $8.0 billion of share repurchases and $6.8 billion of dividends. The annualized dividend rate was raised to $7.52 per share in June 2023.
Material changes and unusual items
- UnitedHealthcare served 1.1 million more people overall. Medicare Advantage enrollment increased 8% to 7.7 million; Medicaid enrollment decreased 4% to 7.8 million, primarily amid resumed eligibility redeterminations.
- The MCR increased from 82.0% to 83.2%, reflecting elevated care activity and business mix. Prior-year medical cost estimates developed favorably by $840 million in 2023, compared with $410 million in 2022.
- Acquisition cash spending declined to $10.1 billion from $21.5 billion in 2022. Year-end goodwill and other intangible assets totaled $118.9 billion, approximately 43% of consolidated assets.
- The company completed the sale of its Brazil operations on February 6, 2024. It expects to record an approximately $7 billion loss in the first quarter of 2024, mostly from foreign-currency translation losses accumulated in equity.
- On February 22, 2024, the company disclosed a cybersecurity incident believed to involve cybercrime threat actors. As of the filing date, its investigation was ongoing and it had not determined that the incident was reasonably likely to materially affect financial condition or results.
Outlook, commentary and risks
The filing provides no specific numerical earnings or revenue guidance. Management said increased senior outpatient care patterns observed in 2023 were expected to continue through 2024. It also cited pressure on Medicare Advantage funding from the 2024 final rate notice and the January 2024 advance notice for 2025, as well as possible continued Medicaid margin pressure. Management described medical and operating cost management, benefit and network changes, and county-level decisions on plan offerings as potential responses.
Key risks include mispricing or underestimating medical costs; changes to Medicare and Medicaid funding, rates, enrollment and audit adjustments; extensive regulation and litigation; cybersecurity, privacy and technology risks; provider contracting and competition; and uncertainty in medical-claims reserves. The company’s critical audit matter was the estimation of incurred-but-not-reported medical claims. A hypothetical 1% difference between estimated and actual medical costs payable would have changed 2023 net earnings by approximately $245 million. The financial statements received an unqualified audit opinion, as did the auditor’s opinion on internal control over financial reporting.
Legal and governmental inquiries include a False Claims Act matter alleging improper Medicare risk-adjustment submissions; the company stated it could not reasonably estimate the outcome. The filing notes that loss estimates for some legal and regulatory matters are not reasonably estimable.
Important facts for investors to verify
- Standalone fourth-quarter results and trends, since this filing presents annual figures.
- Subsequent disclosures on the February 2024 cybersecurity incident, including operational effects, costs, recovery and any revised materiality assessment.
- The timing and accounting treatment of the Brazil sale and the expected approximately $7 billion first-quarter 2024 loss.
- 2024 and 2025 Medicare Advantage rate developments, actual medical utilization and MCR, and Medicaid membership and rate trends.
- Medical-claims reserve development and outcomes of government audits, investigations and material litigation.
- Debt maturities, corporate-available liquidity, acquisition commitments and the company’s capital-return plans.